Preventing secondary injury in neurocritical care patients is our first priority.

Developing therapeutic solutions that aim to prevent secondary injury and enable healing in neurocritical care patients.

Our portfolio of innovative neurocritical care solutions includes novel, practical solutions to problems related to secondary injury.

We aspire to provide technologies and interventions to improve outcomes and efficiencies for neurocritical care patients. Our portfolio is built on an expert understanding of desired outcomes and intense focus on unmet needs in neurocritical care.

Coupling care decisions with interventions to provide full therapeutic solutions that drive meaningful outcomes and value.

Our portfolio of innovative neurocritical care solutions includes novel, practical solutions to problems related to secondary injury. Our work is currently targeted at hemorrhagic stroke and tumor, but our technologies have platform applications for other patient populations. We are introducing novel, first-of-their-kind technologies that have the potential to change treatment pathways and outcomes.

1 Centers for Disease Control and Prevention.
2 www.globenewswire.com/news-release/2019/04/29/1811302/0/en/Stroke-Management-Market-Projected-to-Garner-36-75-Bn-by-2023-at-7-1-CAGR-Says-AMR.html

Initial focus: hemorrhagic stroke

  • 15 million people suffer from strokes every year1
  • 20% of strokes are hemorrhagic
  • Projected to grow at 7.7%2

FDA-Cleared for Sale

MindsEye Expandable Port

Developed out of neurosurgeons’ need for deeper access and better visualization. The MindsEye port extends surgical reach while minimizing the impact on surrounding tissue, so you can treat more patients, sooner.

Learn About MindsEye

 

Caution: Federal (U.S.A.) Law restricts this device to sale by or on the order of a physician.

Currently in Clinical Trials

Neurapheresis Therapy

The Neurapheresis Cerebrospinal Fluid (CSF) Treatment Platform is designed to be a safe, device-based alternative for treating debilitating and life-threatening diseases that involve foreign bodies in the cerebrospinal fluid.

Learn About Neurapheresis Therapy

 

Caution: Investigational Device. Limited by Federal (U.S.A.) law to investigational use only.

Currently in Development

DepiCT Neuroimaging Platform

DepiCT uses the power of AI to identify anatomic and physiologic features not available via current methods for more informed decision making.

Learn About DepiCT

 

DepiCT Neuroimaging Platform is currently under development. All subsequent material represents intended use.

Looking to learn more about our neurocritical care technologies? Let’s talk!

Call 651-917-4060 or email neuro@minnetronixmedical.com